rpl1603 Antibody

What is RPL13/rpl1603 and what cellular functions does it perform?

RPL13 (Ribosomal Protein L13) is a critical component of the 60S subunit of eukaryotic ribosomes. In humans, this protein is approximately 24.3 kilodaltons and may also be known by alternative names including BBC1, D16S444E, D16S44E, 60S ribosomal protein L13, and OK/SW-cl.46 . The protein plays an essential role in protein synthesis and ribosome assembly.

The homologous protein in Schizosaccharomyces pombe (fission yeast), designated as rpl1603, serves similar functions in translation but with species-specific characteristics . Both proteins are highly conserved across species, reflecting their fundamental importance in cellular protein synthesis machinery.

The evolutionary conservation of RPL13 is evidenced by the presence of orthologs across multiple species, including plants, flies, canines, porcine, monkeys, mice, and rats . This conservation makes RPL13 a valuable target for comparative studies in cellular and molecular biology.

What types of RPL13/rpl1603 antibodies are available for research applications?

Researchers have access to a diverse array of antibody formats for detecting RPL13 and its homologs:

For S. pombe rpl1603 specifically, polyclonal antibodies raised against recombinant proteins are available with specific reactivity to the fission yeast system . These specialized antibodies are particularly valuable for researchers working with yeast models.

Current data indicates over 132 commercial RPL13 antibodies from at least 21 different suppliers, providing researchers with multiple options to select the most appropriate reagent for their specific experimental needs .

What are the recommended storage conditions for maintaining RPL13/rpl1603 antibody activity?

Proper storage is crucial for maintaining antibody functionality. For RPL13/rpl1603 antibodies, the following storage guidelines are recommended:

• Store at -20°C or -80°C upon receipt for long-term stability

• Avoid repeated freeze-thaw cycles which can damage antibody structure and diminish activity

• Many commercially available antibodies are supplied in protective buffers containing glycerol (commonly 50%) and preservatives such as Proclin 300 (0.03%) to enhance stability

• Working aliquots should be prepared to minimize freeze-thaw cycles

• Storage in manufacturer-provided buffers (typically PBS pH 7.4 with stabilizers) helps maintain functionality

Following these storage recommendations will help ensure consistent performance across experiments and maximize the usable lifetime of the antibody.

What are the validated applications for RPL13/rpl1603 antibodies?

RPL13/rpl1603 antibodies have been validated for multiple experimental applications. The table below summarizes common applications with technical considerations:

For S. pombe rpl1603-specific antibodies, Western blot and ELISA applications have been specifically validated . When planning experiments, researchers should consider that application-specific optimization may be necessary even with pre-validated antibodies.

How can I validate the specificity of RPL13/rpl1603 antibodies in my experimental system?

Validating antibody specificity is crucial for obtaining reliable results. For RPL13/rpl1603 antibodies, consider these methodological approaches:

• Positive and negative controls: Use cell lines or tissues known to express or lack RPL13/rpl1603. For human RPL13, human cell lines provide positive controls, while knockout or knockdown systems serve as negative controls.

• Molecular weight verification: Confirm that the detected band in Western blots corresponds to the expected molecular weight (approximately 24.3 kDa for human RPL13) .

• Peptide competition assay: Pre-incubate the antibody with the immunogen peptide to demonstrate signal specificity.

• Orthogonal detection methods: Compare antibody results with mRNA expression data or multiple antibodies targeting different epitopes of the same protein.

• Cross-species validation: For studies involving multiple species, verify antibody reactivity across the relevant species. Many commercial RPL13 antibodies react with human, mouse, and rat proteins .

For S. pombe rpl1603 studies, species-specific validation is particularly important since antibodies raised against the yeast protein may not cross-react with mammalian systems, and vice versa .

How do polyclonal and monoclonal RPL13 antibodies compare in different experimental applications?

The choice between polyclonal and monoclonal antibodies depends on specific experimental requirements:

Polyclonal Antibodies:

• Recognize multiple epitopes, potentially increasing detection sensitivity

• Often more resilient to variations in protein conformation or mild denaturation

• Particularly useful for applications like Western blotting and immunoprecipitation

• Example: Rabbit polyclonal anti-RPL13 antibodies have shown broad applications in WB, IF, and IHC with reactivity across human, mouse, and rat samples

Monoclonal Antibodies:

• Offer higher specificity to single epitopes

• Provide higher consistency between batches

• Often preferred for quantitative applications requiring reproducibility

• Example: Anti-RPL13 monoclonal antibody [EPR8828] has been cited in multiple publications and validated for WB, ICC, IF, and IHC-p applications

Recombinant Antibodies:

• Combine specificity advantages of monoclonals with potential for engineering

• Typically show higher batch-to-batch consistency

• Example: RPL13 Recombinant Rabbit Monoclonal Antibody has been validated for WB, ICC, and IHC-p applications across human, mouse, and rat samples

For precise epitope targeting, recombinant monoclonal antibodies may offer advantages, while polyclonal antibodies often perform better in applications where protein denaturation may occur.

What approaches can optimize antibody selection for ribosomal proteins like RPL13/rpl1603?

Selecting antibodies for ribosomal proteins presents unique challenges due to their conserved nature and incorporation into large ribonucleoprotein complexes. Consider these methodological approaches:

• mRNA display technology: This technique allows for ultrahigh enrichment efficiency (10^6- to 10^8-fold per round) when selecting antibodies from recombinant libraries. This approach has been successfully implemented using microfluidic systems and can yield high-affinity antibodies in just 1-2 selection rounds .

• Epitope accessibility analysis: When studying assembled ribosomes, select antibodies targeting epitopes that remain accessible in the assembled complex. Structural bioinformatics analysis can help identify these regions.

• Cross-reactivity assessment: For RPL13 studies across species, carefully evaluate sequence conservation at the epitope level. The same antibody may show different performance between human and model organism samples.

• Non-overlapping antibody combinations: Similar to approaches used with SARS-CoV-2 antibodies, using combinations of non-competing antibodies that bind to different epitopes can increase detection sensitivity and specificity . This approach is particularly valuable for challenging targets.

• Antigen affinity purification: Antibodies purified against the specific target antigen, as seen with both RPL13 and rpl1603 antibodies, generally demonstrate higher specificity for their intended targets .

When possible, validate antibody performance against recombinant or purified target protein before application in complex biological samples.

How can I troubleshoot inconsistent results with RPL13/rpl1603 antibodies in immunoblotting experiments?

Inconsistent results when using RPL13/rpl1603 antibodies may stem from multiple factors. The following methodological troubleshooting approach is recommended:

• Sample preparation optimization:

  • Ensure complete protein denaturation using sufficient SDS and heat

  • Consider additional reducing agents to fully expose epitopes

  • For membrane-associated ribosomal fractions, optimize detergent selection and concentration

• Blocking optimization:

  • Test alternative blocking agents (BSA vs. milk proteins)

  • Adjust blocking time and temperature

  • Consider specialized blocking reagents for problematic antibodies

• Signal enhancement strategies:

  • Implement signal amplification methods such as biotin-streptavidin systems

  • Optimize antibody concentration through careful titration

  • Extend primary antibody incubation time (overnight at 4°C often improves results)

• Control experiments:

  • Use recombinant RPL13/rpl1603 as positive controls

  • Include loading controls appropriate for your experimental system

  • Consider utilizing knockdown/knockout samples as negative controls

• Antibody validation:

  • Test multiple antibodies targeting different epitopes

  • Verify antibody lot-to-lot consistency with manufacturer

  • Consider testing both monoclonal and polyclonal antibodies to compare performance

For particularly challenging applications, combining multiple non-competing antibodies against RPL13/rpl1603 may improve detection reliability, similar to approaches demonstrated for other proteins .

What considerations are important when using RPL13/rpl1603 antibodies for immunoprecipitation studies?

Immunoprecipitation (IP) experiments with RPL13/rpl1603 require special consideration due to the protein's incorporation into large ribosomal complexes:

• Lysis condition optimization:

  • Standard RIPA buffers may disrupt ribosome integrity

  • Test milder non-ionic detergents (0.5-1% NP-40 or Triton X-100)

  • Include RNase inhibitors to maintain RNA-protein interactions if studying intact ribosomes

  • Buffer ionic strength affects complex stability (150-300mM NaCl range)

• Antibody selection criteria:

  • Not all antibodies perform equally in IP applications

  • Polyclonal antibodies often outperform monoclonals for IP

  • Specific antibodies validated for IP include Ribosomal Protein L13 (SS-09) with citations supporting IP applications

• Technical protocol considerations:

  • Pre-clearing lysates reduces non-specific binding

  • Protein A/G selection should match the antibody species (Protein A for rabbit, Protein G for mouse)

  • Crosslinking antibodies to beads prevents antibody co-elution

  • Gentler elution methods preserve protein-protein interactions

• Validation approaches:

  • Confirm IP efficiency by immunoblotting input, unbound, and eluate fractions

  • Mass spectrometry analysis of immunoprecipitated complexes can identify RPL13/rpl1603 interaction partners

  • Reciprocal IP with known interaction partners strengthens findings

For studies focused on S. pombe rpl1603, species-specific optimization is crucial as protocols established for mammalian systems may require adjustment for yeast cells .

How can RPL13/rpl1603 antibodies be utilized in studies of ribosome biogenesis and function?

RPL13/rpl1603 antibodies offer powerful tools for investigating ribosome biology:

• Subcellular localization studies:

  • Antibodies enable tracking of RPL13/rpl1603 movement between nucleolus, nucleoplasm, and cytoplasm

  • Combining with markers for different cellular compartments provides insights into ribosome assembly pathways

  • Both IF and ICC applications have been validated for multiple commercial antibodies

• Ribosome assembly analysis:

  • Antibodies can monitor incorporation of RPL13/rpl1603 into pre-ribosomal particles

  • Sucrose gradient fractionation followed by immunoblotting reveals distribution across assembly intermediates

  • Co-IP experiments identify assembly factors interacting with RPL13/rpl1603

• Translational regulation research:

  • Polysome profiling combined with RPL13/rpl1603 immunoblotting links ribosome composition to translational activity

  • CHIP-seq approaches using these antibodies can map ribosome associations with specific mRNAs

  • Ribosome heterogeneity studies benefit from quantitative analysis of RPL13/rpl1603 incorporation

• Comparative studies across species:

  • Antibodies recognizing conserved epitopes enable evolutionary studies

  • S. pombe rpl1603-specific antibodies facilitate yeast model research

  • Human RPL13 antibodies with cross-reactivity to mouse and rat expand model organism applications

The high conservation of ribosomal proteins makes RPL13/rpl1603 antibodies valuable tools for both fundamental research and comparative studies across different experimental systems.

What emerging technologies are enhancing the development and application of antibodies for ribosomal proteins?

Several technological advances are improving antibody research tools for ribosomal proteins like RPL13/rpl1603:

• Microfluidic antibody selection:

  • Integration of mRNA display with microfluidic systems has achieved ultrahigh enrichment efficiency (10^6- to 10^8-fold per round)

  • This technology enables isolation of high-affinity, specific antibodies in just 1-2 selection rounds

  • Applications extend beyond protein-protein interactions to include protein-DNA and protein-drug interactions

• Non-competing antibody combinations:

  • Structural characterization using cryo-EM facilitates development of antibody combinations that bind simultaneously to different epitopes

  • This approach enhances detection sensitivity and improves experimental robustness

  • Similar strategies have proven successful for other protein targets, such as SARS-CoV-2 spike protein

• Recombinant antibody technology:

  • Recombinant production ensures consistent performance between batches

  • Allows for antibody engineering to enhance affinity, specificity, or add functional tags

  • Several RPL13 recombinant rabbit monoclonal antibodies are now available with validation across multiple applications

• Advanced immunogen design:

  • Computational epitope prediction improves antigen selection

  • Peptide immunogens targeting specific accessible regions of RPL13/rpl1603 enhance antibody specificity

  • Structural biology insights guide development of antibodies that recognize native protein conformations

These technologies are expanding the toolkit available to researchers working with ribosomal proteins and improving the reliability of antibody-based detection methods.

What are the key considerations for selecting the optimal RPL13/rpl1603 antibody for specific research applications?

When selecting an RPL13/rpl1603 antibody, researchers should consider:

• Experimental application compatibility:

  • Verify the antibody has been validated for your specific application (WB, IF, IHC, IP, etc.)

  • Review available literature and citations demonstrating successful use in similar contexts

  • Consider application-specific requirements (e.g., recognition of denatured vs. native protein)

• Species reactivity requirements:

  • Confirm reactivity with your experimental species (human, mouse, rat, S. pombe)

  • For cross-species studies, select antibodies with validated reactivity across all relevant species

  • Species-specific antibodies may offer advantages for specialized model systems

• Technical specifications:

  • Consider antibody format (polyclonal vs. monoclonal vs. recombinant)

  • Review immunogen information to understand what region of the protein is targeted

  • Evaluate purification method (antigen affinity purification generally preferred)

• Validation evidence:

  • Assess the extent of validation data provided by manufacturer

  • Review published literature citing the specific antibody

  • Consider additional validation that may be necessary for your application

By systematically evaluating these factors, researchers can select the most appropriate RPL13/rpl1603 antibody for their specific experimental needs, maximizing the likelihood of successful outcomes and reliable data.

How should researchers document and report RPL13/rpl1603 antibody usage in scientific publications?

To enhance reproducibility and transparency in research using RPL13/rpl1603 antibodies, follow these documentation practices:

• Comprehensive antibody identification:

  • Report manufacturer name and location

  • Include complete catalog/product number

  • Specify antibody clone designation for monoclonals

  • Note lot number when relevant to interpretation

• Detailed methodological reporting:

  • Document exact dilutions used for each application

  • Specify incubation conditions (time, temperature)

  • Describe blocking reagents and conditions

  • Detail detection methods and reagents

• Validation documentation:

  • Describe controls used to confirm specificity

  • Include images of full blots with molecular weight markers

  • Document any additional validation performed

  • Address potential cross-reactivity issues

• Reagent accessibility:

  • Consider depositing custom antibodies in repositories

  • Provide source information for all critical reagents

  • Disclose any material transfer agreements or restrictions